Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ in the US, Redefining Image Clarity in 2D Intracardiac Imaging
IRVINE, Calif., May 21, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced the U.S. launch of the SOUNDSTAR CRYSTAL™ Ultrasound Catheter for intracardiac echocardiography (ICE) imaging in cardiac ablation procedures.
The device provides clearer, enhanced image quality compared to other ICE cathetersii, representing an advanced 2D ICE catheter. Integrated with CARTO™ 3 Mapping Systemi, including the CARTOSOUND™ FAM module for enhanced mapping capabilities powered by AI1,iii, SOUNDSTAR CRYSTAL™ provides an efficient workflowi. CARTOSOUND™ FAM enables automatic generation of the left atrial anatomy by a novel artificial intelligence algorithm using images collected from a rotation of the ultrasound catheter in the right atrium, simplifying the integrated workflowi for electrophysiologists performing cardiac ablation procedures for patients1.
"We are proud to advance our legacy in integrated ultrasound catheters with this latest innovation that equips electrophysiologists with the tools they need to promote patient safetyii and drive effectiveiv results," said Jasmina Brooks, President, Electrophysiology, Johnson & Johnson MedTech. "The superior image qualityi,ii , improved catheter maneuverabilityii and stability of the SOUNDSTAR CRYSTAL™ Ultrasound Catheter, along with seamless CARTO™ 3 System integrationi can help enable a zero fluoroscopy workflowiv,v,†,2,3,4,vi, enhancing procedure effectiveness and safety for both healthcare professionals and patients they treat."
ICE is broadly used in catheter ablation procedures to visualize the heart in high resolution to monitor catheter-tissue contact and ablation in real-time and quickly detect procedural complications. When real-time imaging is integrated with a 3D electroanatomical mapping system, such as the CARTO™ 3 System, ICE can help reconstruct cardiac anatomy and enable zero-fluoroscopy proceduresv†,2,3,4. ICE-guided electrophysiology procedures can be performed under conscious sedation, without requiring esophageal intubation and additional anesthesiavii,5.
"During the cases I performed with the SOUNDSTAR CRYSTAL™ Ultrasound Catheter, I was impressed by the clear visualization, tissue definition and enhanced far field imagingi, and full integration with other platforms. Integration with the CARTO™ 3 System provides clear, high-resolution imagesi,viii which simplify the anatomical mapping processix and procedure workflowv," said Amin Al-Ahmad, MDx, St. David's HealthCare, Austin, TX.
The SOUNDSTAR CRYSTAL™ Ultrasound Catheter is the latest addition to a comprehensive portfolio of ultrasound solutions at Johnson & Johnson MedTech. The company recently brought forward the NUVISION™ Catheter, which harnesses advanced 4D imaging to assist physicians performing cardiac procedures, such as Left Atrial Appendage Closure (LAAC).
Cardiac arrhythmias are a growing epidemic. AFib alone is the most common type of cardiac arrhythmia and impacts more than 50 million people worldwide, and 8 million people in the U.S6. AFib is a progressive disease, and if left untreated can get worse over time or lead to other serious complications like heart disease or stroke7,8. Catheter ablation is a safe and effective procedure to restore the heart's incorrect electrical signals, which causes an abnormal heart rhythm9.
About SOUNDSTAR CRYSTAL™ SOUNDSTAR CRYSTAL™ is an ultrasound catheter that features an 88-element phased linear array to deliver outstanding image quality and detailed visualization of intricate anatomical structures inside the hearti. SOUNDSTAR CRYSTAL™ is integrated with the CARTO™ 3 System for a cohesive and efficient workflow during catheter ablation procedures. The catheter also is designed with optimal balance of stiffness and flexibility, ensuring precision in maneuverabilityi.
Cardiovascular Solutions from Johnson & Johnson MedTechAcross Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit biosensewebster.com and connect on LinkedIn and X, formerly Twitter.
About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in surgery, orthopaedics, vision and cardiovascular solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. Biosense Webster, Inc. is a Johnson & Johnson MedTech company.
Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding SOUNDSTAR CRYSTAL™. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of healthcare products and services; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.sec.gov, jnj.com or on request from Johnson & Johnson.
© Johnson & Johnson and its affiliates 2025. All rights reserved. US_ELP_ULTR_399314
i Based on Siemens' internal report CRF data responses as of 8/9/2024. CRF Data PN 11291187-EPT-021.ii When compared to [ACUSON AcuNav™ Ultrasound Catheter] [SOUNDSTAR™ Ultrasound Catheter]iii CARTOSOUND™ FAM Module uses Deep Learning, which is a subset of AIiv Safety profile refers to complication and primary adverse event rates†Efficacy profile refers to acute success (pulmonary vein isolation) and long-term success.v Based on a survey of 31 physicians.vi Johnson & Johnson and its affiliates' portfolio of products with FDA approved/cleared instructions for use to support fluoro alternative workflows when used with the CARTO™ 3 System include the following: THERMOCOOL SMARTTOUCH™ SF Catheter, THERMOCOOL SMARTTOUCH™ Catheter, CARTO™ VIZIGO™ Bi-Directional Guiding Sheath, PENTARAY™ NAV ECO High Density Mapping Catheter, OCTARAY™ Mapping Catheter with TRUEref™ Technology, OPTRELL™ Mapping Catheter with TRUEref™ Technology, DECANAV™ Mapping Catheters, and Webster™ CS Catheter.vii Based on a meta analysis of ICE applications in EPviii When compared to SOUNDSTAR™ Catheterix Based on 96 surveys, by 31 EPs with an average score of 5.0 or higher on 7-point Likert scale with 5=Satisfied 6/7=Completely Satisfiedx Dr. Al-Ahmad serves as a consultant for Johnson & Johnson but was not compensated for this announcement.
1 CARTOSOUND™ FAM Module Instructions for Use. UG_5462-018H P02. November 2023.2 Debreceni D, Janosi K, Bocz B, et al. (2023). Zero fluoroscopy catheter ablation for atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med;10:1178783. doi: 10.3389/fcvm.2023.1178783.3 Rajendra A, Hunter TD, Morales GX, et al. (2023). Steerable sheath visualizable under 3D electroanatomical mapping facilitates paroxysmal atrial fibrillation ablation with minimal fluoroscopy. J Interv Card Electrophysiol;66(2):381-388. doi: 10.1007/s10840-022-01332-8.4 Tahin T, Riba A, Nemeth B, et al. (2021). Implementation of a zero fluoroscopic workflow using a simplified intracardiac echocardiography guided method for catheter ablation of atrial fibrillation, including repeat procedures. BMC Cardiovasc Disord;21(1):407. doi: 10.1186/s12872-021-02219-8.5 Tong Hu, Tongshuai Chen, Kellina Maduray, Wenqiang Han, Jingquan Zhong. Intracardiac Echocardiography: An Invaluable Tool in Electrophysiological Interventions for Atrial Fibrillation and Supraventricular Tachycardia. Rev. Cardiovasc. Med. 2024, 25(6), 191. https://doi.org/10.31083/j.rcm2506191.6 Mensah, G, Fuster, V, Murray, C. et al. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J Am Coll Cardiol. 2023 Dec, 82 (25) 2350–2473.7 Calkins, H., et al (2017). 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart rhythm, 14(10), e275–e444.8 Odutayo, A. et al (2016). Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ (Clinical research ed.), 354, i4482.9 Natale, A. et al (2014). Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. Journal of the American College of Cardiology, 64(7), 647–656.
Media Contacts:
Erin Farleyefarley1@its.jnj.com
Majo EcheverriaMechever@its.jnj.com
Investor Relations:Tracy MenkowskiInvestor-relations@its.jnj.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-medtech-launches-soundstar-crystal-in-the-us-redefining-image-clarity-in-2d-intracardiac-imaging-302461244.html
SOURCE Johnson & Johnson MedTech
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
CCC Appoints Tech Leader Barak Eilam to Board of Directors
CHICAGO--(BUSINESS WIRE)-- CCC Intelligent Solutions Holdings Inc. (CCC) (NASDQ: CCCS), a leading cloud platform provider for the insurance and automotive industries, is pleased to announce the appointment of Barak Eilam to its Board of Directors. A seasoned technology executive and former CEO of NICE Ltd., Eilam brings more than two decades of experience in enterprise software, artificial intelligence (AI) and customer-engagement technologies. Mr. Eilam adds proven capabilities as CCC continues to scale growth from its strategic investments in AI, the CCC IX Cloud™ and its connected ecosystem. 'We are excited to welcome Barak to our Board as an independent director,' said Githesh Ramamurthy, Chairman and CEO of CCC. 'His experience scaling and driving customer-centric innovation will be a terrific addition to our ability to serve clients and help fuel our next phase of growth.' During his decade-long tenure as CEO of NICE, the company became an undisputed leader in AI-powered customer experiences, serving more than 25,000 organizations in more than 150 countries. Mr. Eilam led NICE through a period of accelerated growth, achieving nearly a threefold increase in revenue and a sevenfold rise in market capitalization. 'It's an honor to join CCC's Board at such a dynamic time,' said Eilam. 'CCC's laser focus on delivering value to its customers—reflected in its high customer satisfaction and retention—is truly impressive. I'm excited to support the company's mission to drive meaningful impact across the broader insurance and automotive industries.' The addition of Mr. Eilam reflects CCC's commitment to maintaining a Board of Directors with experienced and forward-thinking leaders to support the company's vision for growth and market expansion. Added Ramamurthy, 'As we welcome Barak, we also extend our sincere thanks to Chris Egan, who stepped down from the Board in March. We are deeply grateful for Chris's steadfast guidance, leadership and support since joining the board in 2017 as part of Advent International, L.P.'s investment in CCC.' About CCC CCC Intelligent Solutions Inc. (CCC), a subsidiary of CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCCS), is a leading cloud platform provider for the multi-trillion-dollar P&C insurance economy, creating intelligent experiences for insurers, repairers, automakers, part suppliers, and more. The CCC Intelligent Experience (IX) Cloud™ platform, powered by proven AI and an innovative event-based architecture, connects more than 35,000 businesses to power customized applications and platforms for optimal outcomes and personalized experiences that just work. Through purposeful innovation and the strength of its connections, CCC technologies empower the people and industry relied upon to keep lives moving forward when it matters most. Learn more about CCC at Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding future use and performance of CCC's digital solutions. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, competition, including technological advances and new products marketed by competitors; changes to applicable laws and regulations; and other risks and uncertainties, including those included under the header 'Risk Factors' in CCC's filings with the Securities and Exchange Commission ('SEC'), including the Form 10-K filed February 25, 2025, which can be obtained, without charge, at the SEC's website ( The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Yahoo
2 hours ago
- Yahoo
Harmonic Announces Reporting Date for Second Quarter 2025 Results
SAN JOSE, Calif., July 14, 2025 /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced it will release its second quarter 2025 financial results after the market close on Monday, July 28, 2025. Harmonic will host a live webcast to discuss the Company's results at 2:00 p.m. PT on the same day. To participate via telephone, please register in advance using this link, Upon registration, telephone participants will receive a confirmation email detailing how to join the audio version of the webcast, including the dial-in number and a unique registrant ID. The live webcast will be available via Harmonic's Investor Relations website at The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call. For those unable to participate in the live event, a replay will be available on the same website after 5:00 p.m. PT. Further information about Harmonic and the company's solutions is available at About HarmonicHarmonic (NASDAQ: HLIT), the worldwide leader in virtualized broadband and video delivery solutions, enables media companies and service providers to deliver ultra-high-quality video streaming and broadcast services to consumers globally. The company revolutionized broadband networking via the industry's first virtualized broadband solution, enabling operators to more flexibly deploy gigabit internet service to consumers' homes and mobile devices. Whether simplifying OTT video delivery via innovative cloud and software platforms, or powering the delivery of gigabit internet services, Harmonic is changing the way media companies and service providers monetize live and on-demand content on every screen. More information is available at Harmonic, the Harmonic logo and other Harmonic marks are owned by Harmonic Inc. or its affiliates. All other trademarks referenced herein are the property of their respective owners. View original content to download multimedia: SOURCE Harmonic Inc.
Yahoo
2 hours ago
- Yahoo
UGREEN Debuts Nexode Retractable Series - Your Hassle-free Travel Power Kit
BELLEVUE, Wash., July 7, 2025 /PRNewswire/ -- UGREEN, a leading innovator in consumer electronics, today unveiled the UGREEN Nexode Retractable Series which redefines cable management and features industry-leading cable durability. The series, comprising a 65W charger, 145W car charger, a 100W charging cable, and a 165W 20,000mAh power bank, sets new benchmarks for convenient portable power and combines to create a hassle-free travel power kit. Leading the series, the UGREEN Nexode Retractable Series Power Bank 20000mAh 165W combines three charging methods in one: a built-in 100W retractable USB-C cable, a 100W USB-C port, and a USB-A port. Designed for busy professionals and travelers, this powerhouse enables simultaneous fast charging for three devices. It delivers 100W via the retractable cable to charge a MacBook Pro 14-inch (M4) to 54% in just 30 minutes. Its 20,000mAh capacity sustains demanding workflows, while the tangle-free and space-saving retractable mechanism maintains organization across seven preset lengths. For streamlined mobility, the UGREEN Nexode Retractable Series 65W Charger features two USB-C ports and one USB-A port, in addition to an integrated 2.3ft retractable USB-C cable that delivers up to 65W high-speed charging. This compact solution powers a MacBook Air (M4) to 84% in 60 minutes using GaNInfinity technology for up to 95% energy efficiency. Eight-layer safety protections and real-time thermal monitoring ensure robust reliability. Designed for car users with multiple devices to charge, the UGREEN Nexode Retractable Series 145W Car Charger combines a 60W retractable USB-C cable, two USB-C ports, and a USB-A port to deliver 145W total output, simultaneously charging laptops, tablets, and phones. The 2.3ft cable adjusts across eight preset lengths to eliminate dashboard clutter, while its flame-retardant casing and six-layer protection ensure safety. Completing the ecosystem, the UGREEN Nexode Retractable USB-C Cable 100W delivers 100W PD fast charging to high-demand devices while supporting USB 2.0 data transfers at 480Mbps. It is precision-crafted with a reinforced jacket and comes with abrasion-resistant terminals for real-world reliability. More than just powerful, the Nexode Retractable Series is designed for simplicity. Each product features UGREEN's durable retractable system, which eliminates cable clutter and delivers reliable, universal power right when you need it. This focus on practical innovation makes daily charging effortless, whether you are a productivity-focused professional keeping a workspace tidy, a traveler packing a neat and organized bag, or a home user creating a streamlined charging station. Pricing and Availability The UGREEN Nexode Retractable Series launches today. UGREEN offers up to 30% off for Prime Day. UGREEN Nexode Retractable Series Power Bank 20000mAh 165W: $69.99 (MSRP $99.99, Save 30%)UGREEN Nexode Retractable Series 65W Charger: $34.99 (MSRP $49.99, Save 30%)UGREEN Nexode Retractable Series 145W Car Charger: $34.99 (MSRP $49.99, Save 30%)UGREEN Nexode Retractable USB-C Cable 100W: $11.99 (MSRP $15.99, Save 25%) All products will be available on and About UGREEN Since 2012, UGREEN products have seamlessly integrated into millions of people's lives, supporting them at home, work, and on the road. From fast charging to smart storage, UGREEN continually provides reliability and performance you can depend on. With a user-focused approach at its core, the brand has earned the trust of over 200 million users worldwide. For more information, please contact:Gabrielle Wang(NA market): Polina Zhang(EU market): View original content to download multimedia: SOURCE UGREEN GROUP LIMITED Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
